Ynes Helou, Ph.D.

Ynes Helou, Ph.D. has a diverse background in research and industry. Starting in 2008, they were a Future Talent Intern at Merck, followed by a Research Intern at Harvard Medical School. In 2009, they began their Ph.D. Candidate role at Brown University, where they employed quantitative mass spectrometry (MS)-based phosphoproteomic technologies to understand T cell receptor signaling. In 2015, they became a Postdoctoral Fellow at UCSF, where they led research projects looking to mechanistically understand signaling downstream of the T cell receptor. In 2020, they joined Rheos Medicines as a Scientist II, Immunology, where they designed and executed IND-enabling in vitro pharmacology and mechanism of action studies characterizing the impact of MALT1 inhibition on Treg function. In 2022, they will start their role as Senior Scientist, T Cell Function at Clade Therapeutics.

Ynes Helou, Ph.D. obtained their Doctor of Philosophy in Molecular Pharmacology and Physiology from Brown University between 2009 and 2015. Ynes also holds a Bachelor of Science in Biochemistry from Emmanuel College (Boston), which they earned between 2005 and 2009.